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Abstract
Background: During the late summer 2012, a number of medical microbiological laboratories (MMLs) reported an
unusual increase in cases of cryptosporidiosis, a gastrointestinal infection caused by the protozoan parasites
Cryptosporidium spp. Prompted by this signal, the National Institute of Public Health and the Environment (RIVM)
started an epidemiological investigation into possible causes. Simultaneously, samples diagnosed at MMLs were
sent to RIVM for genotyping, aiming to further identify the possible source of the increase.
Methods: Genotyping was performed by sequencing a fragment of the GP60 gene. Additional genotyping was
performed on a subset of samples using six microsatellite markers. Population genetic analysis was performed using
BEAST.
Results: The majority of the samples were typed as C. hominis, and a single GP60 genotype (IbA10G2) largely
predominated. Genotyping microsatellite markers further supported the circulation of a single genetic type.
Population genetic analysis with genotypes found in previous years is inconsistent with a decrease in effective
population size.
Conclusions: The conclusion of this finding is that the rise reflects more an overall increase and not a common
source outbreak.
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Background
Cryptosporidium spp. are protozoan parasites and are
widespread in a diverse range of hosts such as mammals
including humans, birds and fish. In the host Crypto-
sporidium spp. can cause gastro-enteritis with symptoms
of diarrhoea, abdominal pain, nausea and fever [1]. Be-
cause of the global distribution of Cryptosporidium spp.,
these parasites can infect humans everywhere around
the world.
There are more than twenty recognized species of Crypto-
sporidium [2, 3]. These species differ remarkably in their
host specificity. Indeed, some species have a strong prefer-
ence for a limited range of hosts, such as C. hominis, found
almost exclusively in humans, whereas others, such as C.
ubiquitum will infect a very broad range of hosts including
rodents, cattle and humans [4, 5]. Humans are mostly in-
fected by C. parvum and C. hominis [6–9]. C. hominis was
first recognized as a distinct strain of C. parvum, only
found in humans. Other C. parvum strains are not
restricted to human hosts and can also be found in cattle
and other animals [10, 11]. Later, C. hominis was recog-
nized as a distinct species [4].
Human cryptosporidiosis in Europe occurs with sea-
sonal peaks, particularly in August and September [12].
Seasonal peaks in The Netherlands have been reported:
an increase of cryptosporidiosis in the spring, mainly
caused by C. parvum and a peak late in the summer and
the start of the autumn, caused both by C. parvum and
C. hominis [7]. Detailed reports of seasonal peaks in the
UK have been published [13–15]. Similar patterns have
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been described in other parts of the world as well, for in-
stance in California (USA) and New Zealand [16, 17].
Next to sporadic cases, outbreaks of cryptosporidiosis
can occur, often through contact with contaminated water
containing infectious oocysts. Outbreaks of cryptosporidi-
osis as a result from a single source contamination occur
occasionally in western European countries. Such out-
breaks have recently been reported in Norway, Sweden
and Spain [18–20]. Typical sources can be food, contami-
nated swimming pools or recreational water. Water-borne
outbreaks are frequently reported worldwide [21, 22].
In 2012 a number of medical microbiological labora-
tories (MMLs) reported an unusually high increase of
cases of cryptosporidiosis starting in August. A rise of
cryptosporidiosis in August is to be expected but the
diagnostic laboratories reported an increase beyond the
ordinary. Based on collected data from eight laboratories
that used the same detection method since 2010, a rise
of more than three times of the number of patients com-
pared to previous years was observed [23]. The National
Institute of Public Health and the Environment (RIVM)
also started a case–control study to identify possible
sources of Cryptosporidium contamination but found no
evidence of a single source outbreak [23]. Additionally,
the MMLs sent in the Cryptosporidium-positive samples
for genotyping, intended to assist the epidemiological in-
vestigation. Here, we present the results of a molecular
characterization of the Cryptosporidium spp. isolates
during that late summer increase.
Methods
Sample collection
Eighteen MMLs sent in Cryptosporidium spp.-positive
samples, starting in August 2012. The majority were
collected in August but some samples were already
collected in July. Sample collection continued until the
beginning of December. These samples were sent to
the RIVM as either stool or DNA extracts. In case stool
samples were received, we isolated DNA using the
High Pure PCR template DNA isolation kit from Roche
(Almere, The Netherlands) according to the manufac-
turer’s instructions.
Species determination
We performed a real-time duplex PCR with dual labeled
probes on a Roche LightCycler 480 apparatus to determine
whether the species was C. parvum or C. hominis. We used
a combination of a PCR on C. parvum, developed by
Hadfield et al. [24] and a PCR we developed specifically for
C. hominis. The C. parvum specific PCR targets a gene for
a hypothetical protein and the C. hominis PCR targets part
of the GP60 gene. The primers and probes are listed in
Table 1. Each 25 μl reaction contained 10 picomoles (pmol)
of each C. parvum primer, CRULib13F and CRULib13RCp
and 7.5 pmol of probe CRULib13TMCp, 15 pmol of each
C. hominis primer, ChomGP60F and ChomGP60R and 10
pmole probe ChomGP60Tp. We used the LightCycler
Taqman master kit from Roche. Amplification took 45 cy-
cles with 10 s denaturing at 95 °C, 20 s annealing at 60 °C
and 20 s extension at 72 °C.
GP60 genotyping
Genotyping was performed by sequencing a fragment
of the GP60 gene. We amplified a fragment of ap-
proximately 500 bp using primers ATGFOR and
AL3533REV [25]. We also analysed 22 samples using
a nested PCR with primers AL3531 and AL3535 for
the first round and AL3532 and AL3534 for the
second round leading to a fragment of approximately
850 bp [26]. Primers are listed in Table 1. PCRs
were performed using Qiagen HotStarTaq (Qiagen,
Venlo, The Netherlands). The products were ana-
lyzed on a 1.5 % agarose gel, visualized by GelRed™
Nucleic Acid Gel Stain from Biotium (Hayward, CA,
USA). PCR products were treated with ExoSAP-IT
from USB (Cleveland, USA) according to the manu-
facturer’s instructions. We sequenced the PCR prod-
ucts on a 3700 automated sequencer from Applied
Biosystems (Nieuwerkerk a/d IJsel, The Netherlands),
using the Big Dye Terminator kit according to the
manufacturer’s instructions.
Table 1 List of primers and probes used in this study. Primers
AL3531 and AL3535 are used in the first round and primers
AL3532 and AL3534 are nested primers used in the second
round to amplify part of the GP60 gene. The primers CRULib13F
and CRULib13RCp in combination with probe CRULib13TMCp
amplify and detect specifically a hypothetical gene of C. parvum
whereas primers ChomGP60f, ChomGP60r and probe
ChomGP60Tp amplify part of the GP60 and specifically detect C.
hominis









CRULib13TMCp tatctcttcgtagcggcgta Vic MGB-NFQ
ChomGP60F aaagaacaatgaagaaagccaaa
ChomGP60R ggtagaaggttgggtagcactct
ChomGP60Tp tcaaggtggctccaaaggagacg Texas Red BHQ2
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Microsatellite analysis
To further investigate genetic variability of parasite isolates,
six micro- and mini-satellite markers were analyzed. These
markers correspond to the MS1, MS9, TP14, MM5,
MM18, and MM19 loci. The MS1 marker contains a
GGTGGTATGCCA repeat in the heat shock protein 70
gene located on chromosome 2. The MS9 marker contains
a TGGACT repeat in a 2016 bp gene encoding a hypothet-
ical protein located on chromosome 5. The TP14 marker
contains a CAA repeat in a 8421 bp gene encoding a hypo-
thetical protein located on chromosome 8. The MM5
marker contains a TCCTCCTCT repeat within a 11,418 bp
gene located on chromosome 6. The MM18 marker con-
tains a GGACCA repeat in a 5004 bp gene, also located
on chromosome 8. The MM19 marker contains a
GGAGCT repeat in a 7230 bp gene, again located on
chromosome 8. PCR was performed as previously de-
scribed [27]. The size of each PCR product was estimated
by electrophoresis on a capillary apparatus (QiaXcel;
Qiagen, Milan, Italy) by comparison to size standards.
Each allele was assigned a unique number indicating the
estimated size in base pairs.
Estimating genetic diversity
The genetic diversity of a certain species can be used as
an estimate for its effective population size [28]. Spatial
or temporal changes in the population size of an infec-
tious agent may reflect the dynamics of the prevalence
of the disease (23382432, 23244453, takumi submitted
2015). DNA sequences of GP60 from two different time
points were aligned using the multiple alignment
software MAFFT [29]. Subsequently, the alignments
were analyzed by a molecular evolution approach using
the software Bayesian Evolutionary Analysis by Sampling
Trees (BEAST) [28]. We set Hasegawa-Kishino-
Yamamoto (HKY) model of DNA evolution and a con-
stant mutation rate for each site of the GP60 sequences.
Each simulation took 1,000,000 iterations. We discarded
10 % burn-in and used the rest of posterior samples for
the constant population size as a quantification of the
genetic diversity. A criterion for a satisfactory conver-
gence for this parameter was an effective sample size
greater than 200.
We tested whether the DNA sequences sampled in
2012 indicate a change in the estimated genetic diversity
of C. hominis compared to the previous years. For this, we
subtracted the posterior samples for the constant popula-
tion sizes based on the sequences collected between 2003
and 2005 [7] from the posterior samples based on the se-
quences collected in 2012 for the current study. Propor-
tion of positive differences is an estimate for the
probability that the genetic diversity of C. hominis in-
creased in 2012 compared to the previous years [30].
Results
Origin of samples
The unusually high increase of cryptosporidiosis was re-
ported by MMLs in The Netherlands. Together, these la-
boratories cover most of The Netherlands. A total of
507 samples were received and analysed. Table 2 shows
the origin of samples.
Species identification by real-time PCR
Using a duplex real-time PCR, we determined whether
the samples contained C. hominis or C. parvum. Out of
the 507 samples tested, 410 (81 %) could be typed at the
species level, of which 360 (88 %) were C. hominis and
50 (12 %) were C. parvum.
Genotyping the samples using GP60 sequences and
microsatellite markers
First, genotyping of the Cryptosporidium samples was
performed using the GP60 gene. Approximately half of
the 507 samples (n = 269) were typed. Genotypes are
listed in Table 3. Nearly all samples, 90 % (n = 243), were
C. hominis, which is concordant with the results from
the real-time PCR assay. The predominant C. hominis
genotype was IbA10G2, found in 81 % (n = 218). In total,
16 different genotypes were found, and most of these
were represented by only one or two samples (Table 3).
Table 2 Overview of samples sent to the RIVM. The samples came from different regions of The Netherlands. The middle and
western part of The Netherlands is highly urbanised
Region Samples Typed C. hominis C. parvum IbA10G2 Other
North West 71 46 (100 %) 44 (96 %) 2 (4 %) 36 (78 %) 10 (22 %)
West 29 15 (100 %) 14 (93 %) 1 (7 %) 14 (93 %) 1 (7 %)
Middle 138 65 (100 %) 59 (91 %) 6 (9 %) 53 (82 %) 12 (18 %)
South 89 55 (100 %) 51 (93 %) 4 (7 %) 47 (85 %) 8 (15 %)
South East 115 42 (100 %) 33 (79 %) 9 (21 %) 30 (71 %) 12 (29 %)
East 34 25 (100 %) 23 (92 %) 2 (8 %) 22 (88 %) 4 (16 %)
North East 31 21 (100 %) 19 (90 %) 2 (10 %) 16 (76 %) 5 (24 %)
Total 507 269 (100 %) 243 (90 %) 26 (10 %) 218 (81 %) 52 (19 %)
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The two most common genotypes after IbA10G2 were
the C. hominis type IaA15 (n = 21) and the C. parvum
type IIaA15G2R1 (n = 11).
The unusually high increase of cryptosporidiosis was
reported by microbiological diagnostic laboratories that
cover most of The Netherlands. When the geographical
origin of the different genotypes was analysed, little dif-
ference between the various regions was found (Table 2).
The increase of cases was observed throughout the
country, and the IbA10G2 genotype predominated in all
regions.
A panel of 20 randomly selected samples with the
IbA10G2 genotype was further genotyped at six micro-
satellite markers [27]. Out of the 20 samples, 8 were
typed at all markers, 8 were typed at most but not all
markers, and 4 yielded no amplification. At each of the
markers tested, only one allele was found, with estimated
size of 374 bp (locus MS1), 261 bp (locus MS9), 261 bp
(locus TP14), 210 bp (locus MM5), 233 bp (locus
MM18) and 224 bp (locus MM19). Therefore, a single
multi-locus genotype (MLG) characterized these 16 C.
hominis isolates from 2012.
Analysing genetic diversity
The genetic diversity of the isolates sharing the IbA10G2
genotype was analysed further with samples with the
IbA10G2 genotype that were collected in previous years
[7]. A total of 32 samples was analysed with the same set
of microsatellite markers, except for marker MS9. Of
these, 23 were fully genotyped, 5 were partially geno-
typed and 4 were negative. The estimated size of the al-
leles at each locus were identical to those found for the
IbA10G2 samples collected in 2012.
The mean genetic diversity of the C. hominis isolates
from 2012 was estimated to be 0.022 (95 % highest
posterior density (HPD) = 0.015–0.029), whereas it was
0.015 (95 % HPD = 0.010–0.024) for the C. hominis iso-
lates collected during the previous epidemiological in-
vestigation. The estimated probability that the genetic
diversity of C. hominis increased in 2012 compared to
the previous years was 0.88, thus the probability that it
decreased or remained constant was 0.12.
Discussion
In August 2012, an unusual rise of the number of
cryptosporidiosis cases occurred in The Netherlands. At
the early stage, it was unclear whether such increase was
due to the known seasonality of this infection, i.e. to the
usual summer peak, or to an ongoing, undetected out-
break. In the same period, an increase in cases was also
noticed in Germany and in the UK. As in the
Netherlands, the dominant species in the UK was C.
Table 3 GP60 genotypes found in isolates from the present study and from 2003 and 2005 [7]
Species GP60 genotype 2012 2003–2005 (Wielinga et al.)
Number Percentage Number Percentage
C. hominis IbA10G2 218 81.04 65 82.28
C. hominis IaA14R3 21 7.81 0
C. hominis IeA11G3T3 3 1.12 0
C. hominis IaA15 1 0.37 0
C. hominis IaA24G1R1 1 0.37 0
C. hominis IfA12G1 1 0.37 0
C. hominis IcA5G3R2 0 0 1 1,27
C. hominis IdA14 0 0 1 1,27
C. hominis IdA17 0 0 1 1,27
C. parvum IIaA15G2R1 11 4.09 8 10,13
C. parvum IIaA17G2R1 3 1.12 0
C. parvum IIaA17G1R1 2 0.74 1 1,27
C. parvum IIcA5G3 2 0.74 0
C. parvum IIdA17G1 2 0,74 0
C. parvum IIaA16G3R1 1 0,37 0
C. parvum IIdA18G1 1 0,37 1 1,27
C. parvum IIdA19G1 1 0,37 0
C. parvum IIdA22G1 1 0.37 0
C. parvum IIdA15G1 0 0 0
C. parvum IIdA16G1 0 0 1 1,27
Roelfsema et al. Parasites & Vectors  (2016) 9:138 Page 4 of 6
hominis. The epidemiological study into the cause of the
increase did not reveal a clear common source [23].
Additionally, it seemed unlikely that a single contamin-
ation source, such as a single type of food, could be re-
sponsible for the observed increase not only across The
Netherlands, but also in Germany and the UK.
To gain additional insights, a genetic characterization of
isolates from The Netherlands was undertaken. This re-
vealed that a specific GP60 genotype was clearly predom-
inating, although other GP60 genotypes were also found,
adding up to 19 % of the total. The initial goal was to re-
fine the case definition for the epidemiological survey in
order to strengthen the data leading to a cause. Statisti-
cally significant risk factors, however, were not found [23].
Nevertheless, the finding that 81 % of all cases were
caused by the IbA10G2 genotype may be considered as
compatible with a major single contamination source. We,
therefore, analysed some of the IbA10G2 samples with
microsatellite markers. The analysis of six microsatellite
markers revealed no length polymorphism among samples
from 2012 or from previous years, suggesting that the
IbA10G2 genotype from the Netherlands represents a
genetically homogeneous strain.
Does the high percentage of the IbA10G2 genotype in
Dutch patients simply reflect its overwhelming presence
in the environment? We do not know, but we do know
from previous data from The Netherlands and the
neighbouring region of East Flanders, that this has been
the most commonly identified C. hominis genotype in
the last years. Wielinga et al. 7 presented GP60 genotype
data on Cryptosporidium spp. found in clinical samples
from The Netherlands between the years 2003 and 2005.
The study by Wielinga et al. was conducted differently
from this study. We aimed to type as many samples as
possible from patients diagnosed at a large number of la-
boratories across the country during a limited period of
approximately 5 months. On the other hand, Wielinga
et al. collected samples from a limited number of MMLs,
not covering the entire country, and during several
years. Nevertheless, in these samples the IbA10G2 geno-
type was also the predominant genotype, found in 65
out of the 80 samples from 2003 to 2005. The 2009
study from Belgium also confirms the predominance of
the IbA10G2 genotype, although this was less striking
with 10 of 24 samples [31].
The mean genetic diversity of the 2012 samples was
higher than that of the samples from 2003 to 2005. Al-
though the estimated probability for the increase in the
genetic diversity was less than the threshold of 0.95 by
0.07, the change took place at the same period in which
the incidence rate also increased. This is in line with our
previous findings that indicated that the genetic diversity
of GP60 may be an independent and complementary
measure for quantifying disease incidence [32].
In an outbreak situation, where there is only a limited
number of genotypes involved in the infection of a large
population, one might have expected a short-term de-
crease in genetic diversity rather than an increase. Detailed
genetic analyses of (future) outbreaks of Cryptosporidium
spp. may help us to be able to distinguish between up-
surges and unapparent outbreaks of cryptosporidiosis.
Conclusions
In conclusion, the increase in the number of Cryptospor-
idium-positive patients in 2012 was predominantly
caused by C. hominis genotype IbA10G2. The similar
distribution of Cryptosporidium genotypes was also
identified in previous years. Both the mean genetic
diversity of C. hominis and the number of patients in-
creased compared to the previous years. The conclusion
of this finding is that the rise reflects more an overall in-
crease and not a common source outbreak.
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